Screener
Shattuck Labs, Inc. STTK Q2 2026 earnings
Reported August 11, 2026 · Before market open
Revenue-
EPS-$0.12Beat by $0.00
EPS estimate-$0.12
“The RECEPTIVE-CD1 Phase 2b clinical trial in Crohn's disease is on track to initiate in the third quarter, and is designed to establish the efficacy profile of SL-325 across three dose levels, both at induction and at maintenance time points. As we expected, clinical proof of concept for the TL1A/DR3 axis is now emerging outside of IBD. We are pleased to see this continued momentum for the class, and we believe that blocking DR3 will prove more efficacious than blocking TL1A across any indication where TL1A is implicated.”
Next report
Nov 10, 2026 (in 2 months)Revenue estimate$37.5K
EPS estimate-$0.10
Segments
By segment
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Shattuck Labs, Inc. report Q2 2026 earnings?
- Shattuck Labs, Inc. (STTK) reported Q2 2026 earnings on August 11, 2026 before market open.
- What were Shattuck Labs, Inc.'s Q2 2026 revenue and EPS?
- Shattuck Labs, Inc. reported revenue of - and eps of $-0.12 for Q2 2026.
- Did Shattuck Labs, Inc. beat estimates in Q2 2026?
- EPS beat the consensus estimate of $-0.12 by $0.00.
- How did Shattuck Labs, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 50.0% from $-0.24.
- Where can I find Shattuck Labs, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-055484) and the 10-Q periodic report (0001628280-26-055483) directly on SEC EDGAR. The filing index links above go to sec.gov.
